Pattern separation and frontal EEG change as markers for responsiveness to electroconvulsive therapy by Davis, Kathryn
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Pattern separation and frontal EEG
change as markers for
responsiveness to
electroconvulsive therapy
https://hdl.handle.net/2144/23748
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
PATTERN SEPARATION AND FRONTAL EEG CHANGE AS MARKERS FOR  
 
RESPONSIVENESS TO ELECTROCONVULSIVE THERAPY 
 
 
 
 
by 
 
 
 
 
KATHRYN GORDON DAVIS 
 
B.S., Bates College, 2015 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 KATHRYN GORDON DAVIS 
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 Roberta White, Ph.D. 
 Professor of Neurology  
Chair of Environmental Health, School of Public Health 
 
 
Second Reader   
 Michael Henry, M.D. 
 Psychiatrist 
Director of Somatic Therapy, Massachusetts General Hospital  
 
 
 
 
	  	   iv 
ACKNOWLEDGMENTS 
 
Over the past year I’ve been fortunate enough to meet so many admirable people 
while working towards the completion of my thesis. I would like to extend my deepest 
gratitude towards my primary thesis reader, Dr. Roberta White, a truly remarkable 
woman who has inspired me with her stories and positivity. Her empathy, warmth, and 
encouragement were a constant comfort, particularly on those endless, coffee-fueled 
nights of research. I would also like to thank my secondary thesis reader and primary 
thesis mentor, Dr. Michael Henry, the man who does it all, and who has taught me a great 
deal about being confident, resourceful, and persistent in pursuit of all that I set out to do. 
And of course one cannot forget the unforgettable Michelle Collins-Butman and Jessenia 
Urquiza, who both went above and beyond to offer me help whenever they could. I will 
always appreciate their kindness, good humor and willingness to show me all the ins and 
outs of the ECT department of Psychiatry at MGH. I would also like to give a special 
thanks to David Zhou, who helped me navigate through the mysteries and complications 
of coding and Matlab. As always, I’d like to give a tremendous thank you to my parents, 
who listened patiently to all my explanations, plights, excitement, and doubts, and who 
always had faith in me. Your support in my academic efforts continues to drive me 
towards my greatest aspirations. Last, but not least, thank you to my friends who offered 
me their kindness and support. Thank you. 
 
  
	  	   v 
PATTERN SEPARATION AND FRONTAL EEG CHANGE AS MARKERS FOR 
RESPONSIVENESS TO ELECTROCONVULSIVE THERAPY 
KATHRYN GORDON DAVIS 
ABSTRACT 
 There is still a great deal that is unknown about various depressive conditions, 
though it is a very common affliction and cause of disability throughout the world. Not 
only do the underlying mechanisms of various types of depression remain uncertain, but 
the mystery of how different treatment options work and who will respond to them also 
persists. The aim of this study was to identify potential non-invasive biomarkers, to 
predict responsiveness to electroconvulsive therapy. Two hypotheses were investigated in 
this study. The first was that patient improvement from baseline on the neurocognitive, 
computer based pattern separation task prior to the third ECT treatment will correlate 
with a clinical antidepressant response. The second was that increased prefrontal slowing 
relative to baseline will correlate with a decrease in depressive symptoms. As a first step 
to validate this approach, a healthy control group performed both the pattern separation 
and EEG tasks once per week over the course of three weeks. Patient participants 
completed both tasks before their first ECT treatment, prior to their third treatment, and 
prior to their last treatment. A spectral analysis of EEG data was then conducted. Results 
indicated good test-retest reliability for the pattern separation task and EEG 
measurements across all three trials in the healthy control group. Results from patient 
data are inconclusive, but indicates that there is a change from baseline to subsequent 
trials for at least the EEG measurements. However, a larger sample size is needed to 
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determine this. The limited results from this small patient sample suggest that these 
measurements may have clinical value in refining ECT treatment, and merit further study. 
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INTRODUCTION 
 
Depression: Impact and Prevalence 
 
Depression is one of the most common of human afflictions (Rotheneichner et al., 
2014).  Approximately 350 million individuals world wide are affected by depression, 
including conditions such as major depressive disorder, bipolar disorder, dysthymia, 
cyclothymic disorder, seasonal affective disorder, as well as depression associated with 
illness (WHO, 2016; Mayo Clinic, 2016). Of these people, 10-15% will experience 
recurrent depression throughout their entire lifetime, leading to a deep socioeconomic 
strain (Silverstein et al., 2015; Joshi et al., 2016). Consequences of chronic, moderate to 
severe depression have profound effects in the psychological, physical, and 
socioeconomic functioning of the individual (WHO, 2016). In addition to being the 
second leading cause of disability throughout the world, it is also a risk factor for 
ischemic heart disease and is associated with an increased risk of suicide (Silverstein et 
al., 2015; Ferrari et al., 2013). Tragically, more than 800,000 people each year die from 
suicide, and is one of the leading causes of death in individuals between 15 and 29 years 
old (WHO, 2016). Depression is a major source of disability, illness, and death across the 
globe (Nordanskog et al., 2010).    
There are a variety of treatment options for those affected by depression, 
including cognitive behavioral therapy, antidepressant medication, and neuromodulation. 
However, due to severity and heterogeneity of the illness, insufficient numbers of trained 
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professionals and resources for treatment, and social stigma, over half of the afflicted 
individuals worldwide are untreated (WHO, 2016).  Additionally, the rates of various 
depressive conditions, like major depressive disorder and bipolar disorder, along with 
other mental health conditions, have been increasing across the globe, and yet, 
knowledge of the pathogenesis of major affective illness is still limited (WHO, 2016; 
Drevets, Price, and Furey, 2008). 
 
Neurocircuitry of Mood Disorders 
 
Early studies hypothesized that particular neurochemicals and peptides were 
responsible for the underlying pathology of major depression (Mayberg, 2003). However, 
as more research has been conducted, models for depression have become increasingly 
more complex, with data suggesting that the disorder cannot be pinpointed to any one 
particular structure or neurotransmitter system in the brain (Mayberg, 2003). Current 
theories now look at depression as a multifaceted disorder that involves dysfunction of 
distinct, yet connected, pathways within the brain, as well as multiple neurotransmitter 
systems. In the face of this dysfunction, the remaining systems within the brain are 
unable to compensate for a decline in emotional regulation during times of stress 
(Mayberg, 2003). This model of neurocircuitry is consistent with data from post mortem 
studies, as well as studies involving neuroimaging, particularly fMRI (Drevets et al., 
2008; Zhong, Pu, Yao, 2016). These models have indicated that both structural and 
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functional abnormalities influence the development of mood disorders (Drevets et al., 
2008).   
Both major depressive disorder and bipolar disorder usually involve major 
depressive episodes, which are believed to involve various brain systems that regulate 
mood, attention, expression of emotions, reward processing, motivation, social 
awareness, response to stress, and other functions like sleep or appetite (Drevets et al., 
2008). Although the disturbances affecting these brain systems are not yet clear, genetics, 
injury during development, temperament, and environmental stress are all thought to play 
a role (Mayberg, 2003). Furthermore, studies have found abnormal neurophysiology, 
neurochemisty, and neuropathology in patients suffering from both major depression and 
bipolar depression (Drevets et al., 2008).    
A meta analysis by Seminowcz et al., (2004) found that many studies have 
reported frontal and cingulate changes in depressed patients as well as other limbic and 
subcortical structures, though these are reported less frequently. Abnormalities of these 
structures found during the pretreatment state were often normalized upon antidepressant 
treatment, thus providing evidence for their role in various depressive conditions 
(Seminowicz et al., 2004). These studies suggest that there are complex interactions 
between these brain areas, types of treatment, and responsiveness of the brain to 
treatment (Seminowicz et al., 2004). Further neuroimaging, neuropathological 
assessments, and lesion studies have suggested that emotional behavior is regulated in 
part by the limbic-cortical-striatal-pallidal-thalamic (LCSPT) circuit. This circuit includes 
connections between brain structures such as the amygdala, hippocampus, orbital and 
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medial prefrontal cortex (OMPFC), ventromedial striatum, ventral pallidum, and 
mediodorsal and midline thalamic nuclei (Drevets et al., 2008; Zhong et al., 2016).  
The LCSPT circuit was initially believed to have a role in emotional regulation 
due to connections to structures such as the hypothalamus and periaqueductal gray, both 
of which are involved in controlling emotional expression (Drevets et al., 2008; Price and 
Drevets, 2010).  Both human and animal models have found associations between 
emotional expression and regulation and structures within this brain circuitry, particularly 
with the orbital frontal cortex, medial prefrontal cortex, and the anterior cingulate cortex 
(Murrough, Iacoviello, Neumeister, Charney, and Iosifescu, 2011). Lesion studies 
involving the LCSPT circuit have supported its hypothesized role in mediating emotional 
behavior and expression. For example, early lesion studies in monkeys examining the 
lateral temporal cortex and medial temporal lobe structures, such as the hippocampus and 
amygdala, showed that such lesions produced an apathetic response in the animals 
(Kluver and Bucy, 1939). Imaging studies of older adults with lesions in, or connected to, 
this circuitry have been carried out in patients with degenerative basal ganglia disorders, 
such as Parkinson’s and Huntington’s disease, and in individuals with cerebrovascular 
injury to their striatum and orbital cortex (MacFall, Payne, Provenzale, and Krishnan, 
2001; Folstein, M. F., Robinson, Folstein, S., and McHugh, 1985). These patients had an 
increased risk of experiencing a major depressive episode. In particular, deep white 
matter lesions in the orbital cortex were associated with the severity of depression 
(MacFall et al., 2001). Furthermore, a meta-analysis exploring the association of the 
LCSPT circuit in depression by Zhong et al., found that drug-naïve patients with major 
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depression had decreased fMRI activation within this circuit (2016). This suggests that 
this neurocircuitry may be a directly involved in the mechanism of depression, rather than 
a target of the effects of antidepressant pharmacological treatment (Zhong et al., 2016). 
Furthermore, fMRI studies of patients with major depressive disorder have found 
decreased activity particularly within the dorsolateral prefrontal cortex, a structure 
included in the LCSPT circuitry. This area has been linked to cognition, regulation of 
mood, and decision-making, and is one of the most consistently detected regions of 
abnormality in patients with major depression (Zhong et al., 2016).  
It is thought that modifying this circuit is important for remission of mood 
disorders, and certain pharmacological, deep brain stimulation, and surgical treatments 
help to inhibit abnormal activity within extended cortical circuits that connect with the 
LCSPT circuit (Mayberg, 2003; Drevets et al., 2008). Neuroimaging studies have also 
found that these extended cortical circuits play a role in anxiety disorders that often 
accompany depression (Drevets et al., 2008). As research continued to build upon 
knowledge of the limbic system and its projections to other brain areas, investigators 
have hypothesized that the medial prefrontal cortico-striato-pallido-thalamlic circuit was 
vastly intertwined with the amygdalo-striato-pallido-thalamic circuit, and to constitute the 
main circuitry involved in mood disorders (Price and Drevets, 2010). 
Consistent with the above functional abnormalities, patients with mood disorders 
have often been found to have volumetric irregularities in their ventral and medial frontal 
cortices as well as in their hippocampus and other visceromotor network structures, such 
as the amygdala (Mayberg, 2003). However, the degree and location of abnormal 
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morphology depends on factors such as age at onset, genetic predisposition, and whether 
the patient experiences mania or psychosis associated with their depression (Drevets et 
al., 2008). For example, those who develop major depressive disorder and bipolar 
disorder later in life, tend to show non-specific atrophy. However, those who experience 
early onset, non-psychotic, major depressive disorder or bipolar disorder are often found 
to have abnormal volumes in their prefrontal cortex, cingulate, and structures in their 
temporal lobe (Drevets et al., 2008). 
 
A Closer Look at the Hippocampus and its Role in Depression 
 
The hippocampus is a structure within the medial temporal lobe of the brain 
involved in forming, storing, and retrieving memories, as well as applying memories to 
new situations (Kirwan et al., 2012; Yassa and Stark, 2011). Despite its well known role 
in declarative memory, evidence has also shown an association between the hippocampus 
and mood disorders, such as depression. Abnormalities in the hippocampus have been 
found to be associated with depressive episodes (Abbott et al., 2014). Cellular apoptosis, 
decreased neurogenesis, a lower number of glial cells in the hippocampus, atypical 
hippocampal connections, and smaller volumes have been associated with depressive 
disorder (Abbott et al., 2014). Postmortem and neuroimaging research have provided 
evidence for decreased gray matter volume, glial cells, and neuron size, associated with 
the cellular and structural alterations found in depressed patients (Canali et al, 2014). The 
loss of volume in the hippocampus, determined by clinical imaging studies, not only 
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seems to relate to the depressive state of the individual, but also to the duration and 
number of episodes (Nordanskog, Larsson, M.R., Larsson, E.M., and Johanson, 2014). In 
addition, post mortem studies have shown a relationship between stress, depression, and a 
lack of neuroplasticity in the hippocampus (Nordanskog et al., 2014).  The hypothalamic-
pituitary-adrenal axis (HPA) is associated with the body’s management of stress 
(Nemeroff, 1998). Overall, patients with depression have been found to have a 
hyperactive HPA axis causing increased levels of hormones, particularly cortisol 
(Nemeroff, 1996). Observations in animal models demonstrate that high levels of cortisol 
are associated with damage to the hippocampus. Consistent with these findings, human 
imaging studies have shown that, compared to healthy controls, depressed patients have 
smaller hippocampus volumes (Nemeroff, 1998). However, the increased activity of the 
HPA axis in depressed patients tends to normalize towards that of healthy controls upon 
treatment, such as medications or ECT (Nemeroff, 1996). Therefore, it is thought that 
antidepressants and neuromodulation may have a role in stopping these negative changes 
within the brain, and possibly improving symptoms through neurogenesis and repair 
activities (Canali et al, 2014).  
 
BDNF and Depression 
 
Preclinical studies have shown that interventions that increase plasticity in the 
hippocampus have led to an antidepressant effect in animals. However, clinical studies 
have had mixed results. One theory on remission of depression is that increased plasticity 
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allows the neural networks to be repaired, leading to a response to pharmacological 
treatment (Lee, Park, Um, and Kim, 2014). Of current interest is brain-derived 
neurotropic factor (BDNF) and its potential as a biomarker for depression. BDNF is 
important for neuronal growth, survival, and differentiation, as well as neurogenesis and 
plasticity (Molendijk et al., 2011). BDNF has also been found to be related to 
maintaining neurons within brain circuitry involved in emotion, learning, memory, 
appetite and sleep (Molendijk et al., 2011). Many recent studies have indicated a role for 
BDNF in depression and have led to the suggestion that this disorder occurs due to a 
stress related deficit in BDNF (Kurita, Nishino, Kato, Numata, and Sato, 2012; Lee et al., 
2014; Molendijk et al., 2011). Some studies have found that in patients suffering from 
major depression, both plasma and serum BDNF levels are lower than normal, with lower 
levels associated with greater severity of the disorder. In addition, it has been found 
through postmortem studies that suicide victims show lower BDNF levels within their 
prefrontal cortex and hippocampus than controls (Kurita et al., 2012). Clinical studies 
have found that treatment with antidepressants normalizes serum BDNF levels to those of 
healthy individuals (Kurita et al., 2012; Lee et al., 2014). Furthermore, some studies have 
found an increase in serum and plasma BDNF after 6-8 weeks of treatment in responders 
to treatment, leading to the possibility that BDNF levels could be used to predict 
individual treatment outcome (Lee et al., 2014). However, the association between BDNF 
levels and depression are still unclear. Though some studies have found promising 
results, others have found that BDNF levels had no association with depression severity 
(Rapinesi et al., 2015). Furthermore, it remains controversial as to whether BDNF levels 
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are associated with a response to pharmacological treatment or neuromodulation, as 
several studies have found that BDNF levels remain unchanged after ECT or certain 
SSRIs (Zhou et al., 2017; Rapinesi et al., 2015).  
 
Pharmacological Interventions and the Rise of Treatment Resistant Depression 
 
In previous years, mood disorders, like depression, were thought to be due only to 
a neurochemical abnormality. However, newer evidence suggests that structure and 
neuroplasticity also play a role in the disorder and that these two potential underlying 
causes may be overlapping (Nordanskog et al., 2014; Drevets et al., 2008). For example, 
within the brain circuitry thought to be very involved in mood disorders, abnormalities in 
dopaminergic, noradrenergic, serotonergic, cholinergic, GABA-ergic, glutamatergic, 
glucocorticoid and petidergic systems have been associated with depression. Many 
antidepressants are believed to alter these systems. It has been hypothesized that since 
antidepressant medications have a delay in manifesting their effects on mood, there are 
other mechanisms involved, such as a change in plasticity or gene expression (Drevets et 
al., 2008). In addition, there has been some evidence that suggests that pharmacological 
interventions are protective against depression-related hippocampal volume loss (Joshi et 
al., 2016). However, others have found no correlation between volume of the 
hippocampus and an improvement in depressive episodes (Nordanskog et al., 2014).  
Despite the significant advance that antidepressant medications represent in the 
treatment of depression, as many as one-third of those diagnosed with depression are 
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unresponsive to first line pharmacologic interventions (Joshi et al., 2016). Following the 
use of second line treatment options, one third of patients utilizing these options do not 
respond (Joshi et al., 2016). When patients are unable to attain remission of their 
symptoms, despite treatment with interventions that have been shown to be effective for 
their disorder, they are considered to be treatment-resistant (Magnezi, Aminov, Shmuel, 
Dreifuss, and Dannon, 2016). In addition, some patients may show response to treatment, 
without being able to fully achieve remission. Any symptoms that are still experienced 
after the course of treatment then becomes a risk factor for future relapse (Fava, 2003). 
Treatment-resistant depression appears to be an increasing problem, with recent estimates 
of up to 40% of depressed patients suffering. In the past, this estimate was only 
approximately 10-15% (Taylor, 2008). One possibility for such a large increase in 
patients suffering from treatment resistant depression could be increased public health 
measures and awareness, as well as a possible inadequacy in the diagnostic validity of the 
new DSM-V. An analysis by Wakefield (2012), suggested that for depression and grief 
disorders, the DSM-V was lacking in its ability to completely distinguish between normal 
and disordered, increasing the risk of false diagnoses. Further studies are needed to 
confirm the validity of the DSM-V. 
In 1997, Thase and Rush proposed a system for staging treatment resistant 
depression (Thase and Rush, 1997). In the first stage, the patient does not respond to first 
line treatment options. The second stage occurs when the patient fails to respond to a 
different class of drug than was previously tried. In stage three, the patient also fails to 
respond to a tricyclic antidepressant. Stage four is characterized by failure of the patient 
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to respond to a monoamine oxidase inhibitor. Stage five is when the patient cannot 
respond to any of the above treatment options or to electroconvulsive therapy (Thase and 
Rush, 1997). Although this model is helpful in the classification of treatment resistant 
depression, it does not take into account the dose or duration of treatment. Additional 
paradigms staging treatment resistant depression have been developed and expanded 
upon (Fava, 2003). 
 
Electroconvulsive Therapy for Treatment-Resistant Depression 
 
With awareness of treatment resistant depression on the rise, it has become 
increasingly more urgent to utilize treatment options for patients that are not only 
effective, but can induce a faster remission than traditional pharmacological agents. The 
induction of seizures to treat psychiatric conditions dates back to as early as the 1500s, 
with instances of physicians treating mania by instructing patients to ingest camphor 
(Rudorfer, Henry, and Sackeim, 2003). However, modern use of convulsive therapy first 
occurred in the 1930s after neuropsychiatrist Ladislas Joseph von Meduna used camphor 
oil to successfully treat a patient suffering from catatonia. After this success, he 
continued to use convulsive therapy to treat individuals suffering from schizophrenia 
(Rudorfer, et al., 2003). Interestingly, additional studies during the time found that 
schizophrenic patients who developed epilepsy experienced an improvement in their 
symptoms (Kimball, 2016). In 1938, the pharmacologic approach to inducing seizures 
was improved upon by using electricity to initiate them (Kimball, 2016). Clinicians 
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Cerletti and Bini, after first conducting the procedure in animals, tested the efficacy of 
electrically induced seizures in a delusional patient. The patient showed immediate 
improvement and, after eleven more treatments, recovered (Rudorfer et al., 2003).        
Soon after, ECT was used for the treatment of mood disorders and underwent 
great refinement in technique and patient comfort (Kimball, 2016; Rudorfer et al., 2003). 
ECT is now considered to be the most potent biologically based treatment for individuals 
with treatment resistant depression, as well as other psychiatric disorders (Tedonlkar et 
al., 2013; Ende, Braus, Walter, Weber-Fahr, and Henn, 2000). Consistent with this 
viewpoint, a meta-analysis from the UK ECT Review Group (2003) found that ECT was 
significantly more effective in improving symptoms of unspecified depression diagnoses 
than pharmacological agents. In addition, they found that patients electing to receive ECT 
as part of their care were less likely to discontinue treatment compared to those using 
medications alone (UK ECT Review Group, 2003). Although one study found that 
relapse rates between those using only medications and those using ECT were not 
significantly different, ECT ultimately had both faster response and remission rates 
(Kellner et al., 2006; Taylor, 2008). Despite some patients’ resistance to other methods of 
treatment, ECT has led to a 50-70% improvement for patients who fall into the treatment-
resistant category (Tendolkar et al., 2013). However, patient responsiveness to ECT also 
appears to depend on the duration of depressive episodes, whether or not they have 
psychotic depression, or whether patients have previously responded to medications 
(Daly et al., 2001). Nevertheless, it has been reported that depressed patients treated with 
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ECT rate their quality of life as being more improved than those who do not receive this 
treatment (McCall, 2001). 
Despite the quick improvement in treatment-resistant individuals undergoing 
ECT, this method of treatment is often considered controversial due to potential side 
effects  (Ende et al., 2000). Cognitive side effects of ECT can include anterograde 
amnesia, which is typically temporary, and retrograde amnesia, which at times can be 
permanent (Ende et al., 2000). Animal studies of ECS provided additional information 
and demonstrations of side effects associated electric shock. For example, mice trained to 
avoid a foot shock would lose knowledge of their training after ECS was administered 
(Fochtmann, 1994). In addition, the effects of ECS on memory were also tested in mice 
through taste aversion to a toxin put in their water. After ECS, the animal’s ability to 
associate water with the toxin was distorted (Fochtmann, 1994). It is also worth noting 
however, that electrode placement in these animals had an effect on the extent of their 
memory loss and that animals often showed a gradual improvement in their memory over 
time (Fochtmann, 1994). Despite these effects, both post mortem and brain imaging 
studies have shown no signs of brain damage as a result of ECT (Joshi et al., 2016). 
However, although there is no evidence that ECT causes obvious structural alterations 
when observed post-mortem, it does promote mossy fiber proliferation in the 
hippocampus that may be related to its antidepressant effects (Joshi et al., 2016). 
Although the mechanism behind ECT is still largely unknown, there are a few 
theories based on clinical and pre-clinical studies on how ECT elicits its antidepressant 
effects (Tendolkar, 2013). For example, early pharmacological studies found that agents 
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that prevented reuptake or depleted monoamine stores, particularly norepinephrine and 
serotonin, were associated with depressive states in patients (Schatzberg, Garlow, and 
Nemeroff, 2002). It is theorized that ECT treatment either upregulates these 
neurotransmitters or changes the sensitivity of their receptors (Kellner et al., 2012).  The 
neuroendocrine theory postulates that ECT modifies the hypothalamic-pituitary-adrenal 
axis in depressed patients, and the anticonvulsant theory suggests that the actual induced 
seizure during ECT is responsible for the improvement of symptoms (Kellner et al., 
2012). Animal models of ECT have found that electroshock therapy causes increased 
neuro- and synaptogenesis within the hippocampus (Kellner et al., 2012). In addition, 
both animal and human studies have found increased BDNF after ECT treatment. From 
these findings, the neurotrophic theory of ECT was derived, suggesting that ECT works 
through increased neurogenesis and neurotrophic factors in the brain (Kellner et al., 
2012). This suggests that ECT increases neuroplasticity, counteracting the volume loss 
and atrophy of neurons seen in patients with depression (Tendolkar et al., 2013). It is also 
thought that ECT may change brain connectivity (Kimball, 2016). Studies with high-
resolution magnetic resonance imaging (MRI) have found abnormalities in the circuitry 
of frontal regions and subregions of both the hippocampus and amygdala, as well as 
decreased hippocampal volumes, that improve after a course of ECT (Krishnan et al., 
2016; Tendolkar et al., 2013; Nordanskog et al., 2010). However, it is uncertain whether 
the increase in hippocampal and amygdala volume was long-lasting as these studies 
measured volume only the week before and the week after ECT treatment (Tendolkar et 
al., 2013; Nordanskog et al., 2010. The changes in plasticity invoked by ECT treatment 
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have been found to be associated with the patient’s clinical state and the magnitude of 
their response to treatment, suggesting a potential role in ECT’s mechanism of action 
(Joshi et al., 2016).  
 
Mossy Fiber Sprouting: Indicative of Positive or Negative Changes? 
 
One change associated with neuronal plasticity and morphology that has been 
studied in models of ECT and epilepsy is the sprouting of mossy fibers within the 
hippocampus (Vaidya, Siuciak, Du, and Duman, 1999). Mossy fibers are also known as 
dentate gyrus granule cells, which will reorganize their terminal axons upon certain 
stimuli, such as ischemia, stroke, trauma, or temporal lobe epilepsy (Scharfman, Sollas, 
Berger, and Goodman, 2003). Several animal studies have shown a remodeling of the 
hippocampus via mossy fiber changes after ECT treatments, a result that is not seen 
through pharmacological treatments (Ende et al., 2000; Tendolkar et al., 2013). In animal 
epilepsy studies involving kindling or excitotoxin treatment, not only has mossy fiber 
sprouting been observed, but also severe cell death and spontaneous seizures (Vaidya et 
al., 1999). It has therefore been suggested that this change in mossy fiber sprouting 
compensates for cell loss after kindling or excitotoxin treatments (Vaidya et al., 1999). 
Some of these modalities, such as electrical kindling, have also been found to cause a 
secondary or “mirror focus” lesion (Morrell, 1989; Morrell, 1959). In this condition, 
seizure activity arising from a location in one hemisphere of the brain may be related to 
additional seizure activity in a symmetrical area of the other hemisphere (Morrell, 1960).  
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Although these studies show a negative outlook on stimuli such as repeated 
electrical treatments and give reason to view mossy fiber sprouting as a sign of damage to 
the brain, some studies note a difference between epileptic seizures and electroconvulsive 
seizures (Dam, A.M. and Dam, M., 1986). For example, methods used to induce seizures 
in patients or animals during ECT treatment are often very different from induced 
seizures in epilepsy studies. Only in very rare cases do patients treated with ECT 
experience spontaneous recurring seizures after their treatment (Dam, A.M. and Dam, 
M., 1986).  Despite the neuronal loss associated with epilepsy, a meta-analysis conducted 
by Devanand, Dwork, Hutchinson, Bolwig, and Sackeim, (1994) found that neither 
animal nor human studies have found evidence of structural damage or cell loss as a 
result of ECT treatment. A few studies have even suggested that mossy fiber sprouting 
may indicate a positive effect of ECT. A study by Vaidya et al., (1999) found that chronic 
ECS in animals generates mossy fibers in the hippocampus that help to innervate areas 
that were previously lacking neuronal input. Their data suggests that mossy fiber growth 
was not related to cell death, as the mice they treated with chronic ECS experienced no 
cell loss (Vaidya et al., 1999). As previously mentioned, ECT also appears to be related 
to an increase in BDNF, which studies have suggested may also contribute to mossy fiber 
sprouting (Vaidya et al., 1999). This may play a role in protecting the hippocampus by 
helping to increase neuroplasticity, which is typically reduced in depression (Tendolkar et 
al., 2013). Studies have speculated that changes in morphology, cell survival, and 
function of dentate granule cells may contribute to the therapeutic effects of ECT (Vaidya 
et al., 1999). Increased mossy fiber sprouting from the dentate granule cells after ECS 
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may also help the CA3 pyramidal cells of the hippocampus via increased innervation and 
delivery of BDNF; a process that may decrease the risk of stress-induced cell death 
(Vaidya et al., 1999).  
 
Focal Electrically Administered Seizure Therapy (F.E.A.S.T.) 
 
For many years, it was believed that the seizure elicited by ECT was responsible 
for the efficacy of treatment (Nahas et al., 2013). However, studies have found that 
electrode placement, type of electrical stimulus, and strength of electrical stimulation, can 
affect both the antidepressant response and side effects as well (Nahas et al., 2013). In 
addition, it has now been suggested that where the seizure is initiated is more important 
than where it propagates to (Sahlem et al., 2016). Through this research, a new form of 
ECT has been developed known as “Focal Electrically Administered Seizure Therapy” or 
FEAST (Sahlem et al., 2016). FEAST was designed to deliver a more focal and efficient 
electrical stimulus and is suggested to have lesser cognitive side effects than traditional 
ECT, though further studies are necessary to confirm this conclusion (Sahlem et al., 
2016). One factor that may contribute to lesser side effects is that a more focalized 
delivery of electrical stimuli has been found to limit the induced seizure to only the 
prefrontal cortex (Chahine et al., 2014). In addition, FEAST has been found to be less 
efficacious than traditional ECT, thus with a less intense treatment, it can be expected 
that the side effects will be more minimal (Nahas et al., 2013).  
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  FEAST has three distinct differences from traditional ECT: it uses unidirectional 
current instead of bidirectional, it uses a circular anterior electrode and an elongated oval-
shaped posterior electrode, and the placement of electrodes is different than in traditional 
ECT (Sahlem et al., 2016). Additionally, the theory behind FEAST lies in the belief that 
certain neural circuitry, when altered, can help promote an antidepressant response 
(Sahlem et al., 2016). For example, many studies have noted prefrontal changes brought 
about by ECT. In one study utilizing EEG probes, it was found that increased delta waves 
in the prefrontal regions were associated with treatment response (Sackeim et al., 1996). 
Furthermore, when examined by positron emission tomography (PET), reductions in 
glucose metabolic rates particularly in the frontal, prefrontal, and parietal cortexes 
regions correlated with response to ECT, thus suggesting a prominent role for these brain 
regions in the antidepressant response of ECT (Nobler et al., 2001; Henry, Schmidt, 
Matochik, Stoddard, and Potter, 2001). Therefore, FEAST aims to contain the induced 
seizure to the prefrontal region in an attempt to maintain efficacy while minimizing 
cognitive side effects (Sahlem et al., 2016).   
Some of the elements that make FEAST unique also make it potentially more 
efficient than traditional ECT. In an animal study comparing the two treatment methods, 
it was found that the unidirectional current in FEAST is more efficient at inducing 
seizures than bidirectional current used in traditional ECT.  In addition, when comparing 
bilateral ECT to FEAST, the electrode placement and size in FEAST was found to be 
more effective by producing a lower seizure threshold (Spellman, Peterchev, and 
Lisanby, 2009). In a clinical study by Sahlem et al. (2016), FEAST showed adequate 
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efficacy, remission rates, and cognitive side effects, and was found to be both tolerable 
and safe. Other studies have found that although reorientation time, or the time it takes a 
patient to regain awareness of things such as their name, location, birthday, age, or day of 
the week, may be better than traditional ECT and cognitive side effects may be 
diminished, the efficacy may not actually be greater than other forms of ECT (Nahas et 
al., 2013).  Further studies are needed to compare, refine, and optimize this method of 
treatment.  
 
Indicators of Responsiveness and Study Aims 
 
Many studies have strived to discover neurobiological indicators of 
responsiveness to ECT for patients with depression (Silverstein et al., 2015).  One 
interesting finding from various studies indicates that a lower than normal hippocampal 
volume is a predictor of responsiveness for ECT (Silverstein et al., 2015). Despite a 
variety of studies, few findings have been replicated, and further research is necessary to 
accurately identify biomarkers that can be used clinically (Silverstein et al., 2015). This 
study aims to determine whether changes in EEG or pattern separation can be used as 
biomarkers early in treatment to indicate likely positive patient responsiveness to ECT.  
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Pattern Separation Task and its Relation to the Hippocampus 
 
Pattern separation is a process in which memories are condensed into distinct and 
non-superimposable interpretations. It is mediated particularly by the hippocampus, 
though other brain structures may be involved as well. This process helps individuals 
recall and distinguish between memories that are very similar (Brock et al., 2012). It 
leads to the conclusion that a memory is either new and must be stored or is already in 
place and simply needs to be recalled (Das, Ivleva, Wagner, Stark, and Tamminga, 2014). 
In a healthy brain, the hippocampus performs this process quickly and accurately 
(Kirwan et al., 2012). However, there is likely a spectrum across different individuals, 
since memory performance, including pattern separation by the hippocampus, is often 
variable and can be altered by events such as trauma, neuroplasticity, or age (Stark, S., 
Yassa, Stark, C., 2010).   
Although computational models provided the first insight that the hippocampus 
engages in the pattern separation process, evidence from human neuroimaging studies as 
well as studies with memory impaired individuals have provided further confirmation of 
this hypothesis (Brock et al., 2012). For example, Hopkins and Kesner (1993) evaluated 
patients who acquired damage to the hippocampus through hypoxic episodes. These 
patients were told to remember various locations of cities on a map and then asked which 
cities were further north, south, east, or west. Normal control subjects were able to use 
the pattern separation process to delineate between cities that were close to each other in 
distance, while the hypoxic patients showed impairment in determining the location of 
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similarly placed cities (Hopkins and Kesner, 1993). Later, Kirwan and Stark (2007) 
conducted a study using a pattern separation task in concordance with fMRI to provide 
further evidence that the pattern separation process is mediated by the hippocampus.  
Traditionally, studies used pattern separation tasks to compare hippocampal functioning 
between older and younger individuals. Through studies involving hippocampal deficits 
in older patients and through fMRI imaging studies, researchers have been able to 
pinpoint the location of the pattern separation process within the hippocampus to the 
dentate gyrus and CA3 sub-region (Yassa and Stark, 2011; Stark, S., Yassa, Stark, C., 
2010). In young individuals with healthy hippocampi, fMRI shows activation 
demonstrating sensitivity in the DG region of the hippocampus to “lure” objects in the 
pattern separation task, or objects that are similar but not quite the same as objects 
previously shown. Aging studies, such as the study performed by Stark, Yassa, and Stark 
(2010), have provided information regarding the natural changes in function to the 
hippocampus and how these changes impact the ability of the hippocampus to perform 
the pattern separation activity (Yassa and Stark, 2011; Stark, S., Yassa, Stark, C., 2010).  
The pattern separation task utilized in the current study is known as the 
Behavioral Pattern Separation Task, or Mnemonic Similarity Task, developed by Stark 
Lab of Neurobiology and Behavior. The task is designed to evaluate subjects’ ability to 
either recognize previously seen objects or identify objects as being old, new, or similar 
to the initial list of objects presented to them (Stark Lab, 2013). It is believed that this 
assessment reflects changes in connectivity and mossy fiber remodeling in the 
hippocampus, a modification often seen in patients after seizures such as those induced 
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by ECT treatment. To determine changes in functionality of the hippocampus, this study 
will assess patients undergoing ECT through the use of this task at baseline, prior to the 
third treatment, and prior to the last treatment. We hope to determine whether this non-
invasive method of measuring change in hippocampal function can be used to predict 
later antidepressant response for patients undergoing ECT. 
 
Frontal EEG and its Relation to Depression Treatments 
 
In addition, frontal EEG will be assessed as a non-invasive predictor of patient 
responsiveness to ECT treatment. EEG has been an important tool for monitoring patients 
undergoing ECT in particular and has been helpful in preventing prolonged seizures 
during treatment, which can be very unpredictable in patients (Girish, Gangadhar, and 
Janakiramaiah, 2002.) It has also been found that ECT treatment causes an increase in 
frontal activation in those with depression (Casarotto et al., 2013). Despite these findings, 
the relationship between EEG and clinical state remains unclear, although some studies 
have concluded that greater patient responsiveness is correlated with increased EEG 
slowing (Sackeim et al., 1996). 
EEG is not only a tool used to optimize treatment practice but can also provide 
information on mood disorders as well. Both unipolar and bipolar depression have been 
found to have unique EEG characteristics compared to EEGs in healthy individuals (Tas 
et al., 2015). In fact, studies have reported that about 20-40% of depressed patients have 
altered EEG readings that are characteristic of depression (Woźniak-Kwaśniewska, 
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Szekely, Harquel, Bougerol, and David, 2015). For example, unipolar depressed patients 
tend to show increased frontal alpha power, which causes an asymmetry and a lack of 
synchronization in the EEG reading between the two hemispheres. This is a strong 
indicator of diminished activity on the left side of the brain (Tas et al., 2015). Although 
EEG readings have shown differences between bipolar and unipolar depressed 
individuals, bipolar patients’ EEG readings have similarly shown greater activity on the 
right side of the brain than on the left. Because some studies on depression and EEG have 
depicted left frontal sluggishness and overall asymmetrical waves, this EEG pattern has 
been thought to be a biomarker for depression (Tas et al., 2015). After pharmacological 
intervention, several studies have also noted a difference in theta waves in patients who 
responded to treatment, indicating an alteration in activity of the anterior cingulate cortex, 
a structure involved in emotional regulation (Wozniak-Kwasniewska et al., 2015). 
Studies examining patient response to emotional tasks have also found a decrease in both 
unipolar and bipolar patients’ frontal gamma waves, which the hippocampus also 
contributes to (Canali et al. 2015). Some studies have found consistently reduced gamma 
waves, even after patient remission, suggesting that patients’ EEG readings are not 
altered by treatment (Canali et al. 2015). However, other studies have found that EEG 
slowing, indicating increased power of delta and theta waves, usually develops during the 
course of ECT treatment. Variables such as age and the number of treatments may result 
in a greater amount of changes in EEG readings, and it has been found that change in 
EEG reading is transient, with patients’ EEG readings indicating no changes eight weeks 
post treatment (Sackeim et al., 1996). However, the EEG changes induced from treatment 
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imply that synchronization between neuronal groups has occurred, as well as reducing 
their firing rate (Sackeim et al., 1996). Despite the use of EEG as a tool to study the 
characteristics of depression, there are currently very few studies utilizing frontal EEG to 
predict responsiveness to ECT. 
 
Hypotheses: 
 
A. Depressed patients undergoing ECT have a tendency to show decreased 
hippocampal volumes that normalize towards that of controls after treatment. It has been 
found that seizures, like those induced by ECT, can cause an increase in mossy fiber 
sprouting within the hippocampus, which may be one of the underlying causes for the 
antidepressant effects of ECT. Pattern separation tasks reflect change in function of the 
hippocampus by observing whether patients can adequately detect items that are similar 
or different to objects they have previously seen. This study aims to test whether this non-
invasive, computer-based task can serve as a predictor of patient responsiveness to both 
ECT and TMS.  
 
Hypothesis 1: Relative to scores at baseline, patient improvement on the pattern 
separation task prior to the third ECT treatment, will correlate with treatment response 
indicated by at least a 50% decrease in QIDS-SR score at the end of their course of ECT 
treatment. 
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B. Some studies have found that antidepressant response to ECT correlates with 
frontal EEG changes. This study aims to test whether frontal EEG readings measured by 
a Sedline Monitor can be used to predict patient responsiveness to treatment early on in 
the patient’s course of ECT. 
 
Hypothesis 2: Increased prefrontal slowing relative to pretreatment baseline, as measured 
by a Sedline Monitor, prior to the third ECT treatment will correlate with treatment 
response indicated by at least a 50% decrease in QIDS-SR score.  
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METHODS  
 
Participants 
 
 This study planned to recruit 20 healthy volunteers through flyers posted at the 
Massachusetts General Hospital, as well as 20 unipolar and bipolar depressed subjects, 
from patients referred for ECT at MGH by the patients’ clinical treatment teams. After 
the treatment type was decided, patients were asked if they were interested in partaking in 
this research study. Participants ranged in age from 18 to 65 years old (Mean = 36, 
Standard Deviation = 15.92). Other demographic data is shown in Table 1. Each 
participant provided written informed consent, and the Partners Human Research 
Committee/IRB approved the experimental protocol. Inclusion criteria for healthy 
volunteers consisted of a minimum age of 18 years old and being able to provide 
informed consent. Inclusion criteria for depressed individuals included the criteria for 
healthy volunteers with the addition of meeting DSM-V criteria for Major Depressive 
Disorder or Bipolar Disorder. Exclusion criteria for this study for both healthy volunteers 
and depressed individuals included having electroconvulsive therapy within the past six 
months, inability to keep their medications stable for the duration of the study course, a 
significant cardiac condition, history of seizure disorders, adverse reaction to anesthesia, 
history of moderate to severe concussions, a metal object in their skull, history of mild 
cognitive impairments or dementia, and lastly a medical condition associated with 
increased risk for ECT. Participants were asked to complete a brief phone pre-screening 
to determine their eligibility for the study. 
	  27 
Procedure 
  
 Upon arrival to the clinic for a semi-structured clinical interview, subjects were 
given a copy of the study consent form to review. During the screening interview, the 
protocol, risks, and benefits of the study were reviewed in detail and informed consent 
was obtained. Study subjects then completed a brief EEG recording to observe changes in 
brain waves, and a short computer-based neuropsychological task to assess a subtype of 
memory known as pattern separation. For study subjects who enrolled in the study as a 
unipolar or bipolar depressed individual, four symptom rating scales were used to assess 
their change in mood at baseline and throughout the study: the Self Report version of the 
Quick Inventory of Depressive Symptomatology (QIDS-SR), the Young Mania Rating 
Scale (YMRS), the Clinical Global Impression Scale (CGI), and the Mini International 
Neuropsychiatric Interview (MINI). 
 
Symptom Measures  
 
Subjects enrolled in the study as depressed individuals were assessed using four 
symptom rating scales to confirm diagnostic impressions and determine the severity of 
symptoms at baseline and throughout their course of treatment with ECT.  
The Mini International Neuropsychiatric Interview (MINI) was used as part of the 
study subject’s screening visit. Study subjects were evaluated by a board certified 
psychiatrist (MEH) to assess clinical history and confirm eligibility for the study. The 
	  28 
reliability and validity of the MINI was determined by comparing it to the Composite 
International Diagnostic Interview (CIDI) scale (Lecrubier et al, 1997).  
The next three symptom-level scales were completed at baseline, prior to the third 
ECT treatment, and prior to the last treatment. Participants were assessed for manic 
symptoms using the 11-item Young Mania Rating Scale (YMRS), with a clinician 
administering the scale during a brief interview. The YMRS helps determine the severity 
of symptoms based on both the patient’s experience over the past 48 hours as well as the 
clinician’s observations of the patient (Young et al., 1978). The reliability and validity of 
the YMRS was determined by comparing it to the Global Rating, Petterson, and Beigel 
scales. 
Subjects were also assessed using the Clinical Global Impression Scale (CGI). 
This scale is divided into three sections that evaluate severity of illness, change or 
improvement, and response to treatment. The first two sections are rated on a seven point 
Likert scale ranging from 1 (normal) to 7 (very severely ill). The third section is similarly 
rated on a Likert scale, ranging from 0 (improvements with no side effects) to 4 (no 
changes or worse with side effects more pronounced than therapeutic benefits). 
Generally, in clinical and research settings, the first two sections of the CGI are more 
widely used than the final section (Guy, 1976). As in the YMRS, the CGI was 
administered and rated by a clinician during an interview with the patient. Clinical drug 
trials have found the CGI to be an effective measure of illness severity and improvement 
and studies have found the CGI Global Improvement section to be comparable to changes 
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in the Hamilton Rating Scale for Depression (HRSD) scores (Guy, 1976; Spearing, Post, 
Leverich, Brandt, and Nolen, 1997).  
Lastly, subjects were asked to complete the Quick Inventory of Depressive 
Symptomatology (16-item, self-report) to assess for Major Depressive Disorder. The 
QIDS-SR16 asks subjects to answer 16 questions that fall into the 9 diagnostic criteria of 
the DSM-IV: Sadness, concentration, suicidal ideation, self criticism, interest, sleep, 
fatigue, change in appetite or weight, and psychomotor changes (Rush et al., 2003). Each 
question has four possible responses and each response has an associated score from 0 to 
3 points. Subjects are able to score from 0 to 27 total points, with a higher score 
associated with greater symptom severity (Rush et al., 2003).  The QIDS-SR16 has been 
found to be comparable to the 30-item Inventory of Depressive Symptomatology (IDS-
SR30) and the 24-item Hamilton Rating Scale for Depression (HRSD-24). The QIDS-
SR16 was found to be highly sensitive to fluctuation of symptoms and was determined to 
have a high validity (Rush et al., 2003). 
 
Measure of Memory Performance 
 
In addition to the four symptom rating scales, we asked study subjects to engage 
in a computer-based task, conducted on a Hewlett Packard EliteBook laptop, to assess 
memory performance. This task, known as the pattern separation task, was developed by 
C. Stark et al (2007). It’s aim is to test short-term changes in hippocampal functional 
connectivity by evaluating recognition memory of the subjects.  The developers of this 
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task have also studied it under various circumstances, and have found that prior 
knowledge of the task, short-term repeated testing, and most smaller set sizes do not have 
an effect on the results or performance of the subjects (Stark, S., Stevenson, Wu, 
Rutledge, and Stark, C., 2015). For each set, researchers can choose to run it as a 64-item, 
32-item, a 20-item, or a 16-item. Besides the 16-item, which had a lower correlation (R2 
=.24, p=.34), all other set sizes showed similar positive correlations between performance 
and set size (R2 ranged from .55 to .63, with all p values <.01) (Stark et al., 2015).  
There are two phases of the task: a study phase and a test phase. In both phases, 
objects appear on the computer screen one by one, and only remain on the screen for two 
seconds. During the study phase, subjects are asked to identify objects on the computer 
screen by pressing one of two keys on the keyboard to indicate whether the object on the 
screen belongs indoors or outdoors. During the test phase, subjects are again presented 
with objects, but now they are asked to compare this series of objects to the objects seen 
during the study phase. Subjects are instructed to press one of three keys to indicate 
whether an object is old, similar, or new compared to what they saw in the previous 
phase. Subjects are asked to complete this task at baseline, as well as before the third and 
last ECT treatments. All participants completed a 20-item set size and completed sets 1, 
2, and 3 over the span of three weeks. The order of set completion was determined by an 
online random number generator (random.org). The entire task lasts approximately ten 
minutes. 
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Measure of Brain waves via EEG 
 
 Frontal EEG was measured using a Sedline device from Masimo Corporation (52 
Discovery, Irvine, CA 92618, USA). During the measurements, subjects were asked to 
think of something peaceful. Both healthy volunteers and depressed individuals 
completed this task a total of three times. For depressed individuals, this task was 
completed during a baseline assessment, and then repeated prior to the third and last 
treatments.  
 EEG files were then converted from Sedline .PHY files to .EDF files via a 
“phy2edf” conversion program (Purdon Labs, Massachusetts General Hospital) and then 
run through Matlab using an edfread.m function, developed by Purdon Labs, and several 
functions included in the Fieldtrip Matlab Toolbox, developed by Donders Institute for 
Brain, Cognition and Behaviour in Nijmegen, the Netherlands (Oostenveld, Fries, Maris, 
Schoffelen, 2011). Analysis of these files was then conducted via spectral analysis 
functions provided by Chronux Matlab Toolbox, developed by Mitra Lab in Cold Spring 
Harbor Laboratory (Mitra and Bokil, 2008, http://chronux.org/). 	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RESULTS 
 
 
Participant Characteristics 
 
 This study recruited ten healthy volunteers and two depressed patients (one with 
Bipolar Affective Disorder, the other with Major Depressive Disorder) receiving ECT 
treatment at the Massachusetts General Hospital.  The mean ages of healthy control 
participants and depressed patient participants were 34.9 and 41.5 years old, respectively. 
67% of participants were Caucasian, with 83% of participants having at least a college 
degree. See table 1 for further demographic information.  
 
Table 1. Demographic Data 
    Total Healthy 
Volunteers 
Depressed 
Patients 
N  12 10  2 
Gender      
  Male 5 4 1 
  Female 7 6 1 
Mean Age  36 34.9 41.5 
Race/ 
Ethnicity  
     
  White 8 6 2 
  Hispanic 2 2 0 
  African American 0 0 0 
  Asian American 2 2 0 
  Other 0 0 0 
Education 
Level 
     
  High School 
Graduate 
2 2   
  Some College 0 0   
  College Degree 7 5 2 
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  Graduate/ 
Professional Degree 
3 3   
Residence      
  Rural 2 2   
  Urban 8 6 2 
  Suburban 2 2   
          
 
 
Descriptive Data, Outcome Measures 
 
The EEG measurements and pattern separation scores for both healthy controls 
and depressed patients are shown in Tables 2 and 3. The overall average pattern 
separation score (with 100% being the highest score possible) in depressed patient 
participants was numerically, but not quite significantly, lower at baseline (t(10) =1.9023, 
p =.0863) when compared to healthy controls. EEG measurements were made on a 
decibel scale with more negative scores associated with lower power and more positive 
scores associated with higher power.  
A Shapiro-Wilk test was conducted to determine whether the variables for the 
healthy volunteers presented in this study were normally distributed. A normal 
distribution was found for each trial of the pattern separation task in healthy controls and 
for each observed brainwave in all five electrodes across the group of healthy controls, 
except for alpha waves in the FP2 electrode in trial 3, and gamma waves in the FPz 
electrode in trial 2. Subsequent test-retest correlations were conducted using the intraclass 
correlation coefficient and Cronbach’s alpha. 
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Due to the small sample size of the patient participants, we were unable to test 
whether the pattern separation results are normally distributed. This is also the case with 
the brainwaves across each electrode.  
 
Table 2. Mean and Standard Deviation Scores of EEG Measurements in Healthy and 
Depressed Participants 
Means and Standard Deviations for Healthy Controls and Depressed Patients: EEG Measurements  
Healthy Controls  
  FP1 
Alpha 
 FP2 
Alpha 
 FPz 
Alpha 
 F7 
Alpha 
 F8 
Alpha 
 
Baseline 
(n=10) 
-7.612 ±2.741 -7.122 ±2.310 -9.281 ±2.502 -2.544 ±2.888 -3.144 ±2.586 
1 week 
(n=1) 
-6.609 ±1.710 -6.862 ±2.075 -7.528 ±3.205 -1.983 ±2.183 -2.390 ±1.982 
2 weeks 
(n=1) 
-6.562 ±1.442 -7.034 ±1.708 -7.793 ±4.030 -2.418 ±2.284 -2.961 ±1.594 
Depressed Patients  
  FP1 
Alpha 
 FP2 
Alpha 
 FPz 
Alpha 
 F7 
Alpha 
 F8 
Alpha 
 
Baseline 
(n=10) 
-7.501 ±1.332 -5.939 ±0.420 -6.285 ±1.126 -1.735 ±0.144 -1.800 ±0.246 
1 week 
(n=1) 
-4.834  -4.722  2.263  -1.128  1.797  
2 weeks 
(n=1) 
-3.880  -4.840  -5.455  2.093  0.977  
Healthy Controls  
  FP1 
Beta 
 FP2 
Beta 
 FPz 
Beta 
 F7 Beta  F8 Beta  
Baseline 
(n=10) 
-10.990 ±2.383 -10.781 ±2.316 -13.744 ±1.558 -7.391 ±1.812 -8.028 ±2.105 
1 week 
(n=1) 
-11.395 ±1.572 -11.392 ±1.710 -13.061 ±2.47 -7.667 ±2.114 -8.142 ±2.437 
2 weeks 
(n=1) 
-11.087 ±2.395 -11.151 ±2.111 -13.323 ±3.461 -8.196 ±2.461 -8.393 ±2.439 
Depressed Patients  
  FP1 
Beta 
 FP2 
Beta 
 FPz 
Beta 
 F7 Beta  F8 Beta  
Baseline 
(n=10) 
-11.735 ±0.700 -10.878 ±0.001 -13.088 ±1.752 -7.418 ±2.419 -7.402 ±2.179 
1 week 
(n=1) 
-7.422  -5.718  -5.275  -5.129  -4.562  
2 weeks 
(n=1) 
-11.358  -11.812  -8.227  -6.445  -6.856  
Healthy Controls  
  FP1 
Delta 
 FP2 
Delta 
 FPz 
Delta 
 F7 
Delta 
 F8 
Delta 
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Baseline 
(n=10) 
4.781 ±3.128 5.625 ±3.736 2.407 ±1.651 7.834 ±2.503 8.123 ±3.220 
1 week 
(n=1) 
7.617 ±4.406 7.767 ±4.961 5.202 ±3.234 10.063 ±3.311 9.965 ±3.228 
2 weeks 
(n=1) 
8.222 ±3.262 7.441 ±3.752 5.619 ±6.134 9.692 ±3.700 9.728 ±2.737 
Depressed Patients  
  FP1 
Delta 
 FP2 
Delta 
 FPz 
Delta 
 F7 
Delta 
 F8 
Delta 
 
Baseline 
(n=10) 
5.164 ±0.060 7.924 ±2.107 8.061 ±3.265 9.862 ±3.560 9.881 ±0.795 
1 week 
(n=1) 
5.671  5.661  16.539  9.423  13.482  
2 weeks 
(n=1) 
11.823  11.823  8.469  17.895  17.074  
Healthy Controls  
  FP1 
Theta 
 FP2 
Theta 
 FPz 
Theta 
 F7 
Theta 
 F8 
Theta 
 
Baseline 
(n=10) 
-3.380 ±2.399 -2.903 ±2.800 
 
-5.706 ±1.764 -0.084 ±1.649 -0.190 ±2.260 
1 week 
(n=1) 
-1.900 ±2.928 -2.258 ±3.279 -3.758 ±2.879 1.484 ±2.553 0.865 ±2.424 
2 weeks 
(n=1) 
-1.617 ±2.629 -2.390 ±2.698 -4.0761 ±5.255 0.590 ±3.049 0.759 ±2.414 
Depressed Patients  
  FP1 
Theta 
 FP2 
Theta 
 FPz 
Theta 
 F7 
Theta 
 F8 
Theta 
 
Baseline 
(n=10) 
-0.175 ±2.714 -0.274 ±2.837 1.450 ±0.156 4.490 ±3.916 4.029 ±3.746 
1 week 
(n=1) 
-0.472  -0.112  -0.112  4.638  4.638  
2 weeks 
(n=1) 
5.893  4.477  4.583  10.335  9.691  
Healthy Controls  
  FP1 
Gamma 
 FP2 
Gamma 
 FPz 
Gamma 
 F7 
Gamma 
 F8 
Gamma 
 
Baseline 
(n=10) 
-13.151 ±2.442 -12.915 ±2.910 -16.294 ±1.602 -9.780 ±2.268 -10.555 ±2.103 
1 week 
(n=1) 
-13.401 ±1.522 -13.593 ±1.786 -14.256 ±5.053 -10.416 ±2.385 -11.096 ±3.559 
2 weeks 
(n=1) 
-13.858 ±3.243 -13.592 ±3.069 -16.696 ±3.023 -11.479 ±3.122 -12.209 ±2.712 
Depressed Patients  
  FP1 
Gamma 
 FP2 
Gamma 
 FPz Gamma F7 Gamma  F8 
Gamma 
 
Baseline 
(n=10) 
-15.739 ±2.408 -14.90 ±0.157 -18.505 ±3.118 -15.16 ±6.17 -14.16 ±7.37 
1 week 
(n=1) 
-10.442  -6.733  -8.234         -9.69 -7.98         
2 weeks 
(n=1) 
-17.712  -19.081  -5.051                          -13.20    -15.428 
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Table 3. Mean and Standard Deviation Scores of Pattern Separations Scores for Healthy 
Participants (n=10, n=2) 
Means and Standard Deviations for Healthy Controls and 
Depressed Patients: Pattern Separation 
 Healthy Controls 
 Score 
Baseline  71.821 
1 week 73.53777778 
2 weeks 68.99444444 
 Depressed Patients 
 Score 
Baseline 52.995 
1 week 51.175 
2 weeks 
 
67.86 
T-Test for Baseline Pattern Separation Scores Between Healthy 
and Depressed Participants 
t 1.9023 
p .0863 
 
Test-Retest Reliability of the Pattern Separation Task for Healthy Controls 
 
Intraclass correlation coefficients and Cronbach’s alpha were conducted to 
determine the test-retest reliability for the pattern separation task. This task was found to 
have high reliability. Statistical results can be found in Table 4.  
 
Table 4. Measures of Test-Retest for Pattern Separation Scores in Healthy Participants 
(n=10). 
Test-retest correlation for Healthy Controls: Pattern Separation 
Intraclass Correlation Coefficient 
r 0.92 
95% confidence interval .75  to .98 
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F Value  12.29 
p Value <.01 
Cronbach's Alpha 
alpha 0.92 
 
 
Test-Retest Reliability of EEG Measurements for Healthy Controls   
 
 The power of brainwaves, alpha, beta, delta, theta, and gamma, for healthy 
controls were recorded over the course of three separate trials in five different electrodes 
placed over the frontal region of the scalp. Test-retest reliability was determined for each 
brainwave for each electrode using intraclass correlation coefficients and Cronbach’s 
alpha. Brainwaves across all five electrodes were found to be reliable. In depth statistical 
data are shown in Table 5.   
 
Table 5. Measures of Test-Retest for EEG Measurements in Healthy Participants (n=10). 
 
Test-retest correlation for Healthy Controls: EEG Measurements 
Intraclass Correlation Coefficient 
 FP1 Alpha FP1 Beta FP1 Delta FP1 Theta FP1 Gamma 
r 0.83 0.9 0.91 0.77 0.92 
95% confidence 
interval 
.03 to .98 .49 to .98 .60 to .99 -.31 to .98 .59 to .99 
F Value  4.98 8.75 13.39 3.86 10.59 
p Value 0.026 0.005 0.001 0.05 0.003 
 FP2 Alpha FP2 Beta FP2 Delta FP2 Theta FP2 Gamma 
r 0.8 0.87 0.86 0.87 0.89 
95% confidence 
interval 
-.18 to .98 .33 to .99 .25 to .99 .25 to .99 .50 to .99 
F Value  4.25 6.79 6.25 6.3 8.76 
p Value 0.039 0.01 0.01 0.01 0.005 
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 FPz Alpha FPz Beta FPz Delta FPz Theta FPz Gamma 
r 0.63 0.85 0.64 0.59 0.73 
95% confidence 
interval 
-1.21 to .96 .17 to .98 -.98 to.96 -1.6 to .96 -.051 to .97 
F Value  2.5 5.68 2.61 2.24 4.25 
p Value 0.13 0.02 0.12 0.15 0.04 
 F7 Alpha F7 Beta F7 Delta F7 Theta F7 Gamma 
r 0.9 0.95 0.85 0.87 0.79 
95% confidence 
interval 
.47 to .99 .76 to .99 .27 to .98 .46 to .99 .18 to .98 
F Value  8.4 23.65 14.3 9.03 7 
p Value 0.01 <.01 0.001 0.005 0.01 
 F8 Alpha F8 Beta F8 Delta F8 Theta F8 Gamma 
r 0.94 0.92 0.92 0.84 0.81 
95% confidence 
interval 
.71 to .99 .61 to .99 .65 to .99 .20 to .98 .24 to .98 
F Value  14.7 10.95 13.53 5.71 7.22 
p Value 0.001 0.002 0.001 0.02 0.01 
Cronbach's Alpha 
 FP1 Alpha FP1 Beta FP1 Delta FP1 Theta FP1 Gamma 
α 0.8 0.89 0.93 0.74 0.91 
 FP2 Alpha FP2 Beta FP2 Delta FP2 Theta FP2 Gamma 
α 0.77 0.85 0.84 0.84 0.89 
 FPz Alpha FPz Beta FPz Delta FPz Theta FPz Gamma 
α 0.6 0.82 0.62 0.55 0.76 
 F7 Alpha F7 Beta F7 Delta F7 Theta F7 Gamma 
α 0.88 0.96 0.93 0.89 0.86 
 F8 Alpha F8 Beta F8 Delta F8 Theta F8 Gamma 
α 0.93 0.91 0.93 0.83 0.86 
 
 
Relationship between the Pattern Separation Task and the QIDS-SR 
 
Patient participants were asked to complete both the pattern separation task and 
the Quick Inventory of Depressive Symptomology (self-report) for each study visit. At 
this point, there are not sufficient data to conduct correlations between these variables.  
However, as more data are collected, and assuming a normal distribution for pattern 
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separation and QIDS-SR scores, a two-tailed Pearson’s correlation will be conducted to 
evaluate the relationship between the two variables. Current patterns in the data can be 
observed via Figure 1. As previously mentioned, healthy controls had reliable scores over 
the course of the three trials. On average, there was a slight improvement during the 
second trial for these participants, but overall, scores were consistent and high for the 
duration of the study.  
The first patient participant showed no improvement in pattern separation score 
for the first two trials, on which he received a score of 57.78% and 53.57% respectively. 
However, upon the third trial, prior to the last of his ECT treatments, he received a score 
of 67.86%. This patient’s QIDS-SR score also substantially decreased between the first 
and second trials, from 18 to 3 points. However, prior to the last treatment, his QIDS-SR 
score increased to 8 points.  
The second patient participant has yet to have her third study visit, due to 
difficulties with study compliance. During trials one and two, her pattern separations 
scores were 48.21% and 48.78%, respectively. If her scores follow the same pattern as 
the first patient participant, we can expect to see a large increase in her scores upon the 
next trial. In addition, her scores on the QIDS-SR remained in the depressed range during 
the first and second sessions. Her scores were 32 and 33 on trials one and two, 
respectively.  
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Figure 1. Pattern Separation Scores in Healthy and Depressed Patient Participants 
 
 
Relationship between EEG measurements and the QIDS-SR 
 
 As with the pattern separation task, currently there are insufficient data to conduct 
a correlation between EEG measurements and the QIDS-SR. However there does seem to 
be a pattern indicating treatment effect. As more data are collected, assuming a normal 
distribution of the variables, a two-tailed Pearson’s correlation will be conducted to 
evaluate for the associations between each brainwave measured by each electrode and the 
QIDS-SR scores.  
For the first patient participant, a corrupted Sedline data file caused the omission 
of results from the second trial. However, treatment effect can be seen between baseline 
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and third trial measurements. The general pattern is that there is an increase in the power 
of the brainwaves across almost all electrodes.  
 As with the pattern separation trials, the second depressed patient has yet to 
complete the last EEG measurement trial due to the need for more ECT treatment. 
However, even from baseline EEG measurements to the second trial, done just before the 
third ECT treatment, there appears to be a treatment effect that follows the same pattern 
as the first patient participant. Although the changes are sometimes less pronounced than 
in the first participant, as would be expected since these changes were between earlier 
times in her course of treatment, the power of all measured brainwaves tends to increase 
from baseline to the second trial.  
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DISCUSSION 
 
 To our knowledge, this is the first study to utilize both the pattern separation 
computer-based task and frontal EEG, as measured by a Sedline anesthesia monitor, to 
predict remission of depressive symptoms prior to the end of a course of ECT. Based on 
the previous studies showing an effect of ECT on EEG patterns, and the hypothesis that 
pattern separation reflects changes in the hippocampus, this study aimed to assess the 
clinical utility of changes in these two non-invasive measurements to predict 
responsiveness to ECT. The hypotheses of this study were that: 1) relative to baseline, 
improvement on pattern separation scores prior to the third ECT treatment will correlate 
with treatment response measured by the QIDS-SR, and 2) relative to baseline, Increased 
prefrontal slowing, as measured by a Sedline Monitor, prior to the third ECT treatment 
will correlate with treatment response measured by the QIDS-SR.  
 
General Expectations and Actual Findings 
 
Expectations for the healthy control population were that their scores on the 
pattern separation task would remain approximately the same for all three trials. It was 
also expected that the healthy control population would have similar EEG measurements 
across all trials. Therefore, one of the aims of the study was to establish the reliability of 
these two measurements so that they could be confidently assessed in a patient 
population. From the results, we can see that the test-retest reliability of the pattern 
separation task was very good, indicating consistency of the healthy control population 
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across the three trials. This finding was consistent with current literature (Stark et al., 
2015).  
In addition, results also demonstrated excellent test-retest reliability for each of 
the studied brainwaves for each of the five electrodes used during the frontal EEG task. 
Measurements of alpha, beta, delta, theta, and gamma waves in electrode FP1 were found 
to be very reliable over the course of the three trials, with theta waves, slightly less 
reliable than the other brainwaves measured by this electrode. All brainwaves measured 
by the FP2 electrode were also found to have good reliability, though slightly less than 
electrode FP1, across all trials. Alpha waves recorded in FP2 were found to have 
adequate reliability, though less so than other waves recorded with this electrode. Of all 
the electrodes used in this study, FPz was found to be the least consistent and reliable, 
possibly due to the fact that the FPz electrode is used as the ground electrode, which 
serves as a reference point for all other electrodes in the system and is important in 
reducing noise on the recordings (Light et al., 2011). Although alpha, delta, and theta 
waves were not found to have statistically significant reliability as measured by the FPz 
electrode, beta and gamma waves showed adequate test-retest reliability. The F7 
electrode showed very good test-retest reliability across all brain waves measured, with 
gamma waves, indicating slightly less reliability that the other brainwaves measured. 
Lastly, the F8 electrode showed great reliability for each measured brainwave across all 
three trials, with theta and gamma waves slightly less reliable than the other waves 
measured by this electrode. In depth statistical data is shown in Table 5. 
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Expectations for patient participants were that their scores on the pattern 
separation task would increase over the course of their treatment. In addition, it was also 
expected that prefrontal EEG slowing, determined by an increase in power of the slow 
waves, theta and delta, would occur. The small sample size to date precludes a definitive 
analysis. Generally, there is an observable change from baseline measurements in the 
EEG brainwaves recorded across the five electrodes, as well as a change from baseline 
for pattern separation scores. Additional data is needed to apply these findings to the 
general population. 
 
Pattern Separation Scores in Healthy Controls and Patients 
 
To our knowledge, the pattern separation task has yet to be used for studies 
involving mood disorders. It has been used in several aging studies, as well as studies 
involving memory or damage to the hippocampus. Based on these studies, it is evident 
that performance on the pattern separation task is subserved by the hippocampus and by 
several other brain regions. Lesions or damage to the hippocampus have been found to 
disrupt an individual’s ability to complete the pattern separation task (Brock et al., 2012). 
Because this task is thought to be sensitive to changes within the hippocampus, it was 
used in this study to assess potential hippocampal changes brought about by ECT 
treatment.  
As a group, the healthy control population scored an average of 71.82% at 
baseline, 73.54% on trial 2 and 68.99% on trial 3. Other pattern separation tasks reported 
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in the literature have found similar scores on healthy individuals, such as the spatial 
pattern separation task, which found its participants to score within a range of 74% to 
93% (Holden, Hoebel, Loftis, and Gilbert, 2012). As expected, the score of the healthy 
controls in this study remained relatively consistent for the duration of the study (p < 
.01). The two patients, as a group, had much lower scores at baseline than healthy 
individuals, though the two groups are not quite statistically different (p = .0863). The 
average score for patient participants for trials 1 and 2 were 53% and 51.18%, 
respectively. It is worth noting however, that previous studies have found that age can 
have a big impact on pattern separation results (Stark, S., Yassa, and Stark, C. 2010). 
60% of the healthy control group were in their twenties; therefore it’s possible that this 
group had a higher average score due to the affects of age, though this study will continue 
to recruit volunteers and attempt to control for this variable. Despite this possibility, it is 
also well known that depression is often associated with cognitive impairments, in 
domains such as memory and attention (Beblo, Kater, Baetge, Driessen, and Piefke, 
2016), both of which could be the cause of the lower average pattern separation score in 
the patient participants.  
Although the current sample size has prevented any definitive conclusions, the 
first depressed patient participant is interesting because of the timing of his improvement 
on this task. Although the first two trials appeared unremarkable, the first patient’s third 
trial pattern separation score increased to almost the average healthy control score. The 
second patient participant has yet to complete the third trial, as more ECT treatments 
were needed. However, she too demonstrated a similar pattern of low and consistent 
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scores across the first two trials. If this pattern holds true for additional patient 
participants, then we can expect that the greatest change occurs between the second and 
third study trials, or between the third and last ECT treatments. Additional trials may 
more closely pinpoint when the changes in pattern separation scores begin to take place, 
which could increase the accuracy of using this tool as a biomarker for treatment 
responsiveness.  
 
Relationship between the QIDS-SR and the Pattern Separation Task 
 
Although correlations have yet to be conducted until there is an increase in 
sample size, based on QIDS-SR scores, there does appear to be an effect of treatment on 
pattern separation scores. The first patient participant showed a large decrease in QIDS-
SR scores between trials 1 and 2, indicating a decrease in depressive symptoms. 
Although his QIDS-SR score increased a little on the last trial, it was still greatly 
diminished from baseline. It was trial three where the greatest change in pattern 
separation scores occurred. Thus, perhaps improvement of pattern separation scores may 
be more directly correlated with mood improvement. The second patient participant 
remained nearly constant with her QIDS-SR scores and her pattern separation scores 
during the two complete trials. It is expected that when/if her QIDS-SR scores begin to 
decrease, her pattern separation scores will normalize towards those of controls.  
It is also worth considering the possibly of different results between our two 
patient participants due to different baseline depression diagnoses and treatment response 
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rates. According to current literature, a decrease in QIDS-SR score by 50% is necessary 
to consider that the patient is responding to treatment. Furthermore, it was established 
that a score of five or less on the QIDS-SR is considered to be the remission threshold 
(Brown et al., 2008). The first patient in this study had a QIDS-SR score of 18 at 
baseline, which decreased to 3 before the third treatment. Unlike this patient, the next 
patient had a QIDS-SR score of 32 at baseline, which increased slightly, with a score of 
33, prior to the third ECT treatment. Although this patient has shown further 
improvement through the course of treatment, the responsiveness to ECT for this 
individual has been much slower than for the first patient. It may be that her response to 
ECT is different from the first patient participant, and it is possible that this could be 
reflected in her pattern separation scores.  
The first patient was diagnosed with bipolar affective disorder, and the second 
patient with major depressive disorder. It is possible that different types of depression can 
be a factor in the changes to the brain brought about by ECT, thus possibly rendering 
different outcomes. As more data are collected in this study, patients can also be analyzed 
based on their diagnoses and ECT responsiveness to see if there are particular patterns in 
pattern separation scores for different conditions. 
 
Relationship between the QIDS-SR and the EEG Task 
 
As with the pattern separation task, sample size is currently too small to conduct 
meaningful correlations between the QIDS-SR and EEG measurements. However, like 
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the pattern separation scores, it does appear that there was an effect of treatment on the 
EEG measurements. Generally all electrodes showed an increase from baseline in alpha, 
beta, delta, theta, and gamma power. Interestingly, for the first patient participant, delta 
and theta waves, which are in the slower end of the spectrum, appear to have had the 
largest increases in power. For the second patient, there was a pattern of increasing 
brainwave power, but it appears to have been more variable. For electrodes FPz, F7 and 
F8, delta and theta wave power seem to have increased the most in power. However for 
electrodes FP1 and FP2, alpha, beta, and gamma waves seem to have had the greatest 
increase in power. Again, this could be related to the varying rates of treatment response 
between the two patient participants, or may also be due to their differences in the 
pathophysiology of their depressive conditions. EEG measurements can be very unique 
and can also be sensitive to different states or conditions (Teplan, 2002).  
 
EEG Measurements and Laterality in Healthy Controls and Patients 
 
 After the average power for each brainwave for each electrode was calculated, a 
pattern for frontal EEG was observed. In the healthy volunteers, alpha, beta, theta, and 
gamma waves were all found to have a more negative power at the FP1 and FP2 
electrodes, which are placed directly over the left and right eyebrow. For these 
brainwaves, power was found to be less negative when recorded at the F7 and F8 
electrodes, which are placed over the left and right temple. The opposite trend was found 
for delta waves. This finding was unexpected because it suggests that detection of alpha, 
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beta, theta, and gamma brainwaves were more pronounced in the temporal region than 
directly on the forehead. It is possible that this result could be due to noise of the Sedline 
device. However, studies have found that detection of particular brainwaves is sometimes 
greater over different areas of the skull, such as alpha waves, which can be detected more 
so in posterior and occipital regions than other areas (Teplan, 2002).  
Another interesting finding of the healthy controls’ average EEG measurements is 
the fact that delta waves consistently had the most positive values, and thus the greatest 
power of all the waves. Delta waves have a frequency of about 0.5 to 4 Hz, and are 
considered the slowest of the five waves. They have also been associated with sleep 
(Teplan, 2002). In addition, during wakeful states with eyes open, beta is the dominant 
brainwave, but when relaxed with eyes closed, alpha power begins to increase, followed 
by theta and delta when tired or asleep. EEG is very sensitive to different states of 
alertness and can be greatly affected even by closing one’s eyes (Teplan, 2002; Strijkstra, 
Beersma, Drayer, Halbesma, and Daan, 2003). During this study, we asked subjects to 
relax, think peaceful thoughts, and sit with the lights off for the duration of the recording. 
Results seemed to show the effects of this environment, with beta waves being of lower 
power than alpha waves, delta and theta waves having the greatest power, and gamma 
having the lowest power. In addition, a few participants reported feeling that they were 
close to falling asleep. 
Asymmetry of EEG also seems to be fairly common and can be related to 
asymmetrical skull thickness, or other factors (Teplan, 2002; Hagermann, Hewig, Walter, 
and Naumann, 2008). For healthy participants, asymmetry of any brainwave was not 
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apparent. In a few cases, there were differences of approximately 1 to 2 decibels, but this 
was often found only on one of the three trials, and may potentially be related to noise of 
the recording.  
One interesting trend in healthy controls was the small but consistent difference 
between baseline recordings and the second and third trials. Though there was not a 
dramatic difference, the second and third trials on average appear have been much closer 
in power than baseline. This may be attributed to participants becoming more 
comfortable with study procedures as the study progressed. After participants knew what 
they could expect from subsequent study visits, they may have been more able to relax 
during the EEG recording, allowing for more consistent results during trials 2 and 3.  
 The EEG measurements for patients also demonstrated some interesting patterns. 
Similar to healthy controls, alpha, beta, and theta waves in patients were found to be of 
lesser power when measured with the FP1 and FP2 electrodes and higher when measured 
by F7 and F8 electrodes. As in healthy controls, delta waves appeared to have the 
opposite trend. Gamma waves seemed to be more consistent across all the electrodes. In 
addition, the power of the brainwaves measured in depressed patients, except for gamma 
waves, tended to be slightly higher than the healthy controls. This was most apparent in 
theta waves and could perhaps be accounted for by the early morning study visits, when 
the patients may have been very tired. However, current literature indicates that 
differences in theta wave activity may be related not only to antidepressant medications, 
but also to different activity in the anterior cingulate cortex (Woźniak-Kwasniewska et 
al., 2014). This area of the brain is thought to be important for emotional regulation, 
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learning, motivation, reward, and memory, functions which are often disrupted in 
depressed patients. Treatments such as antidepressants and deep brain stimulation have 
been found to increase cerebral blood flow to the prefrontal cortex and the anterior 
cingulate cortex (Mayberg et al., 2005). As in the healthy controls of this study, 
asymmetry of any brainwave was not apparent. 
 
Limitations and Future Suggestions 
 
As a preliminary study using pattern separation and frontal EEG as biomarkers to 
predict responsiveness to ECT, there are a number of limitations and recommendations 
for future studies.  
 Although we plan to continue collecting data from both healthy volunteers and 
patients suffering from major depressive disorder and bipolar disorder, the current sample 
size prohibits confidence in the interpretations of the results. The current demographic 
data shows that this study involved mostly Caucasian individuals with a college or 
professional level degree (see demographic data in Table 1). The aim is to continue 
obtaining data from a diverse group of participants that can accurately represent the 
general population as well as to demographically match the healthy volunteers to the 
depressed patient participants.  
 It is also worth noting that there are a number of variables related to the 
participant that can effect EEG measurements. For example, the methods by which EEGs 
are analyzed can alter the ability to observe potential EEG changes relating to sleep, 
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drugs, psychiatric conditions, cognitive tasks and thought processes, and even 
intelligence (Anokhin, Birbaumer, Lutzenberger, Nikolaev, and Vogel, 1996). This study 
utilized traditional methods of EEG analysis using a power spectogram to observe the 
frequencies of various brain waves. However, other types of EEG analysis, such as 
correlational dimension analysis, may potentially contribute to a deeper understanding of 
the meaning behind participants’ EEG measurements. For example, it has been found that 
this method can pick up on certain neuropsychological patterns that are not detected by 
traditional analysis (Anokhin et al., 1996).  
 It is also important to note that variations in skull thickness between participants 
may have had an impact on interpretation of results. One study by Hagermann et al. 
(2008) found greater skull thickness in the frontal region than the posterior region of the 
head, contributing to less detection of frontal alpha activity. Therefore, differences in the 
frontal skull thickness of participants had a greater effect on the ability of the EEG device 
to pick up alpha waves. In addition to this finding, it was observed that some participants 
of the Hagermann et al. study had asymmetrical skull thickness, causing greater detection 
of alpha waves on the side where the skull was less thick (Hagermann et al., 2008). 
Theory for the effects of skull and intracranial variations on EEG is attributed to Ohm’s 
law, stating that the volume and conduction properties between the brain and the 
electrodes on the scalp have an effect on the recorded electrical potentials  (Hagermann et 
al., 2008).  
 Another limitation of this study is the environment in which volunteers complete 
the study tasks. Though participants are asked to close their eyes and think of something 
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peaceful during the frontal EEG and are asked to try their best with the computer task, the 
rooms are not sound proof, potentially leading to distractions. This is particularly relevant 
for patient participants who complete the study immediately prior to receiving their 
treatment. Though we attempt to minimize any disturbances while they perform the two 
tasks, nervousness over their treatment, conversations with treatment staff, and 
preparations for their treatment may distract them from completing the task to the best of 
their ability. For this reason, as we move forward with the study, all data will be collected 
in the center for perioperative care at Massachusetts General Hospital so that the study 
environment remains consistent.  
 Lastly, this study is limited by the reliance on self-report questionnaires. For 
example, the MINI is limited mainly due to its brief nature and focuses more so on 
current diagnoses instead of lifetime prevalence (Lecrubier et al., 1997).    
 Certain obstacles also occurred while measuring participants’ EEG using the 
Sedline device. Though clearly the device was capable of recording EEG information in 
real time, the device failed to store the information correctly on a few participants’ trials, 
leading to corrupt files that could not be analyzed via a power spectrogram. This further 
reduced sample size.  
 Taking into account the current limitations of this study, the future of this current 
study involves analyzing the pattern separation task and EEG with a larger sample. 
Although this is currently underway, there are several other directions that could be 
pursued. 
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 One possible direction would be to control for any changes in medications during 
treatment. It is possible that the effects of ECT may be stronger than the effects of 
medications. However, it may be beneficial to control for medication changes while 
doing the study, because medication changes might affect the EEG and pattern separation 
task. For example, in a systematic review conducted by Aiyer, Novakovic, and Barkin 
(2016), it was found that a vast range of medications can have effects on the brain waves 
detected by EEG. Antidepressants and mood stabilizers have been found in several 
studies to alter the quality and characteristics of EEG. Buproprion can cause sharp, 
spikey waves or focal slowing patterns on the EEG recording, SSRIs have been found to 
lower theta waves in responding patients, and lithium can increase beta, delta, and theta 
EEG activity (Aiyer et al., 2016). However, practical clinical considerations may not 
permit this approach. 
 As previously mentioned, age also appears to be a prominent factor on participant 
ability to do the pattern separation task and also on variations in EEG measurements. 
Future studies could explore if both EEG and pattern separation have clinical value for 
predicting remission regardless of age, or whether it is more sensitive to a particular age 
group.   
 Although further data collection is needed to draw more definitive conclusions, 
the available data suggests frontal EEG and pattern separation have potential to become 
valuable tools for clinical practice. Given the millions of individuals worldwide who 
suffer from various depressive conditions, such as major depression, bipolar disorder, 
dysthymia and postpartum depression and who are unable to obtain relief through 
	  55 
treatment, the ability for rapidly assessing treatment efficacy is valuable (WHO, 2017).  
Further studies to provide evidence that EEG recordings and/or the pattern separation 
task have utility as biomarkers to predict patient responsiveness to ECT should allow 
refinement in ECT technique that will benefit future patients.  
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